Catheter complications associated with intraperitoneal chemotherapy

European Journal of Gynaecological Oncology

Volumn 19, Issue 3, 1998, Pages 275-279

  Topuz, E ^a   Saip, P ^a,b   Aydiner, A ^a   Salihoglu Y ^b   Yilmaz, T ^b   Topuzlu, C ^b  

^a Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Catheter; Intraperitoneal chemotherapy; Port

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; MITOXANTRONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CATHETER INFECTION; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; OVARY CARCINOMA; PERITONEAL CATHETER; PERITONEUM ADHESION; RETROPERITONEAL FIBROSIS;

ABDOMINAL NEOPLASMS; ADHESIONS; ANTINEOPLASTIC AGENTS; CATHETERS, INDWELLING; FEMALE; FIBROSIS; HUMANS; INFECTION; INJECTIONS, INTRAPERITONEAL; PAIN; RETROSPECTIVE STUDIES;

EID: 0031898317     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Los G. and McVie G. J.: "Experimental and clinical status of intraperitoneal chemotherapy". Eur. J. Cancer, 1990, 26, 755.
2. Markman M.: "Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity". Critical Reviews in Oncology / Hematology, 1993, 14, 15.
3. Markman M.: "Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity". Cancer Treat. Rev., 1986, 13, 19.
4. Kaolan R. A., Markman M., Lucas W., Pfeifie C. and Howel S. B.: "Infectious peritonitis in patients receiving intraperitoneal chemotherapy". Am. J. Med., 1986, 78, 49.
5. Davidson S. A., Rubin S. C., Markman M., Jones W B., Hakes T. B., Reichman B. et al.: "Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system". Gynecol. Oncol., 1991, 41, 101.
6. Piccart M. J., Speyer J. L., Markman M., ten Bokkel Huinink W. W., Alberts D. Jenkins J. et al.: "Intraperitoneal chemotherapy: technical experience at five institutions". Semin. Oncol., 1985, 12 (suppl. 3), 90.
7. Topuz E., Aydiner A., Kizir A., Kardaş H., Öztürk N., Oral E. N., and Dinçer M.: "Local and systemic complications associated with intraperitoneal chemotherapy". Reg. Cancer Treat., 1993, 4. 218.
8. Dedrick R. L.: "Theoretical and experimental bases of intraperitoneal chemotherapy". Semin. Oncol., 1986, 12 (suppl. 4). 1.
9. Pfeiffer P, Amussen L., Kvist-Poulsen H. and Bertelsen K. "Introduction of a new 'single use' delivery system- a preliminary report". Gynecol. Oncol., 1989, 35, 47.
10. Pfeifle C. E., Howell S. B., Markman M. and Lucas W E.: "Totally implantable system for peritoneal access". J. Clin Oncol., 1984, 2. 1277.
11. Runowicz C. D., Dottino P. R . Shafir M. K., Marman M. A and Cohen C. J.: "Catheter complications associated with intraperitoneal chemotherapy". Gynecol. Oncol., 1986, 24, 41.
12. Leyden M. and Sullivan J.: "Full-thickness skin necrosis due to inadvertent interstitial infusion of cisplatin extravasation" Cancer Treat. Rep., 1983, 67, 199.
13. Fields S., Koeller J., Topper R. L., Gurus G. and Vonnoff D. "Local tissue toxicity following cisplatin extravasation". J Natl. Cancer Inst., 1990, 82, 1649.
14. Braly P., Doroshow J. and Hoff S.: "Technical aspects of intraperitoneal chemotherapy". Gynecol. Oncol., 1986, 25, 319.
15. Rubin S. C., Hoskins W. J., Markman M., Hakes T. and Lewis Jr.: "Long term access to the peritoneal cavity in ovarian cancer patients". Gynecol. Oncol., 1989, 33, 46.
16. Almadrones L. and Yerys C.: "Problems associated with the administration of intraperitoneal chemotherapy using the port a cath system". OncoL Nurs. Forum, 1990, 17, 75.
17. Malsmström H., Carstensen J. and Simonsen E.: "Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer". Gynecol. Oncol., 1994, 54, 27.
18. Frasci G., Pacelli R., Scala S., Facchim G., Rinaldi L., Tinessa V. and Biano A. R.: "Intraperitoneal mitoxantrone via temporary catheter in patients with ovarian cancer: toxicity and feasibility evaluation". Advances in Therapy, 1990, 7, 124.
19. Niceletto M. O., Padrini R., Ferrazi E., Nascimben O., Visona E., Tumolo S. et al.: "Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer". Eur. J. Cancer, 1993, 29, 1242.
20. Frasci G., Tortoriello A., Facchini G., Conforti S., Perisco P, Mastrantonio A. and Iaffioli R. V: "Intraperitoneal (IP) cisplatin-mitoxantrone-interferon-alfa 2b in ovarian cancer patients with minimal residual disease". Gynecol. Oncol.. 1993, 50, 60.